Simultaneous determination of moxifloxacin and H2 receptor antagonist in pharmaceutical dosage formulations by RP-HPLC: application to in vitro drug interactions
AUTOR(ES)
Sultana, Najma, Akhtar, Mahwish, Shamim, Sana, Gul, Somia, Arayne, Muhammad Saeed
FONTE
Química Nova
DATA DE PUBLICAÇÃO
2011
RESUMO
Simultaneous determination of moxifloxacin (MOX) and H2-antagonists was first time developed in bulk and formulations. Purospher STAR C18 (250 x 4.6 mm, 5 μm) column was used. The mobile phase (methanol: water: ACN, 60:45:5 v/v/v, pH 2.7) was delivered at a flow rate of 1.0 mL min-1, eluent was monitored at 236, 270 and 310 nm for cimetidine, famotidine and ranitidine, respectively. The proposed method is specific, accurate (98-103%), precise (intra-day and inter-day variation 0.098-1.970%) and linear (r>0.998). The LOD and LOQ were 0.006-0.018 and 0.019-0.005 μg mL-1, respectively. The statistical parameters were applied to verify the results. The method is applicable to routine analysis of formulations and interaction of MOX with H2-antagonist.
Documentos Relacionados
- Simultaneous RP-HPLC determination of sparfloxacin and dexamethasone in pharmaceutical formulations
- Validated method for the determination of Gemifloxacin in bulk, pharmaceutical formulations and human serum by RP-HPLC: in vitro applications
- Simultaneous determination of gemifloxacin and diuretics in bulk, pharmaceutical dosage forms and human serum by RP-HPLC
- Stability indicating HPLC method for simultaneous determination of moxifloxacin hydrochloride and ketorolac tromethamine in pharmaceutical formulations
- RP-HPLC method development and validation for estimation of rivaroxaban in pharmaceutical dosage forms